Edward J.  Sitar net worth and biography

Edward Sitar Biography and Net Worth

Edward J. Sitar holds the position of Chief Financial & Accounting Officer at 9 Meters Biopharma, Inc.

He is also on the board of Timber Pharmaceuticals, Inc.

In the past he held the position of Chief Financial Officer of SchoolCare, Inc., Chief Financial Officer of Ammon Analytical Laboratories, Inc., Vice President-Finance of Vital Signs, Inc., Chief Financial Officer & Treasurer at MIM Corp., Chief Financial Officer & Executive Vice President at Cadent Holdings, Inc., Chief Financial Officer, Secretary & Treasurer for Cancer Genetics, Inc., Chief Financial Officer for BioScrip, Inc., Chief Financial Officer of Active Health Management, Inc. (New York), Chief Financial Officer & Executive Vice President at Cadent, Inc., Senior Manager at Coopers & Lybrand LLP, Chief Financial Officer-New Business at M1 Holdings LLC (Colorado) and Controller at IVAX Pharmaceuticals, Inc.

Mr. Sitar received an undergraduate degree from the University of Scranton.

What is Edward J. Sitar's net worth?

The estimated net worth of Edward J. Sitar is at least $0.00 as of April 5th, 2021. Mr. Sitar owns 179,338 shares of Timber Pharmaceuticals stock worth more than $0 as of April 19th. This net worth approximation does not reflect any other investments that Mr. Sitar may own. Learn More about Edward J. Sitar's net worth.

How do I contact Edward J. Sitar?

The corporate mailing address for Mr. Sitar and other Timber Pharmaceuticals executives is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. Timber Pharmaceuticals can also be reached via phone at (973) 314-9577 and via email at [email protected]. Learn More on Edward J. Sitar's contact information.

Has Edward J. Sitar been buying or selling shares of Timber Pharmaceuticals?

Edward J. Sitar has not been actively trading shares of Timber Pharmaceuticals in the last ninety days. Most recently, on Tuesday, November 23rd, Edward J. Sitar bought 15,000 shares of Timber Pharmaceuticals stock. The stock was acquired at an average cost of $0.46 per share, with a total value of $6,900.00. Learn More on Edward J. Sitar's trading history.

Who are Timber Pharmaceuticals' active insiders?

Timber Pharmaceuticals' insider roster includes John Koconis (CEO), Alan Mendelsohn (Insider), and Edward Sitar (Director). Learn More on Timber Pharmaceuticals' active insiders.

Edward J. Sitar Insider Trading History at Timber Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2021Buy15,000$0.46$6,900.00View SEC Filing Icon  
See Full Table

Edward J. Sitar Buying and Selling Activity at Timber Pharmaceuticals

This chart shows Edward J Sitar's buying and selling at Timber Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Timber Pharmaceuticals Company Overview

Timber Pharmaceuticals logo
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.87
Low: $0.34
High: $2.94

2 Week Range

Now: N/A

Volume

26,307 shs

Average Volume

511,937 shs

Market Capitalization

$1.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03